Risk Factors of Gastrointestinal Bleeding in Patients Receiving New Oral Anticoagulants.
10.7704/kjhugr.2018.18.4.219
- Author:
Ju Yup LEE
1
Author Information
1. Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea. leejygi@naver.com
- Publication Type:Review
- Keywords:
Apixaban;
Dabigatran;
Edoxaban;
Gastrointestinal hemorrhage;
Rivaroxaban
- MeSH:
Anticoagulants*;
Atrial Fibrillation;
Dabigatran;
Drug Interactions;
Embolism;
Gastrointestinal Hemorrhage;
Hemorrhage*;
Humans;
Liver;
Platelet Aggregation Inhibitors;
Proton Pumps;
Risk Factors*;
Rivaroxaban;
Stroke;
Venous Thrombosis;
Warfarin
- From:The Korean Journal of Helicobacter and Upper Gastrointestinal Research
2018;18(4):219-224
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
New oral anticoagulants (NOACs) are now widely used for the prevention and treatment of venous thrombosis, and for the prevention of stroke and systemic embolism in patients with atrial fibrillation. As compared with warfarin, NOACs have the advantage of rapid onset of action and less drug interaction. However, they carry a higher risk of gastrointestinal (GI) bleeding than warfarin. The risk of GI bleeding in patients using NOACs varies according to the type and dose of the drug. By contrast, apixaban and edoxaban are reported to carry similar risks as warfarin, and the risks with dabigatran and rivaroxaban are higher than that with warfarin. In patients using NOACs, old age, impaired renal function, impaired liver function, concurrent use of antiplatelet agents, and nonsteroidal anti-inflammatory drugs are considered major risk factors of GI bleeding, and gastroprotective agents such as histamine-2 receptor antagonist and proton pump inhibitor have preventive effects. To prevent GI bleeding associated with NOACs, the characteristics of each NOAC and the risk factors of bleeding should be recognized.
